Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011
Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
With the deal, Myriad will acquire RBM's biomarker discovery platform as well as its pipeline of proprietary protein biomarker-based diagnostics, including two tests that a Myriad official said were "relatively close to commercial launch."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rules-Based Medicine Withdraws IPO
November 12, 2010 / ProteoMonitor - Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor